Clinical Trial

Now Enrolling: A clinical trial with the potential to improve outcomes for patients with triple-negative breast cancer who have received prior therapies

MER-XMT-1660-1: A Clinical Trial of Emiltatug Ledadotin (Emi-Le; XMT-1660); Dose Expansion Cohorts Currently Enrolling Participants with Recurrent Triple-Negative Breast Cancer

Trial Information

An antibody-drug-conjugate, or ADC for short, is a type of drug designed to target and kill cancer cells expressing a specific antigen, or biological marker (otherwise known as a biomarker).

ADCs are different from traditional chemotherapy drugs.

Emiltatug ledadotin (also known as Emi-Le or XMT-1660) is an investigational ADC that is designed to target cancer cells expressing the biomarker B7-H4. Emi-Le is currently not approved by the FDA or any other regulatory authority for the treatment of cancer.

The ongoing clinical trial is evaluating the safety and efficacy of Emi-Le in adult patients with recurrent advanced or metastatic triple-negative breast cancer.

ct-image-01
Click here to email Emi‑Le@mersana.com for more information

The trial consists of 2 parts:

Part 1 is known as the “dose escalation” portion, and it evaluated the safety and preliminary efficacy of Emi-Le in cancer patients receiving multiple dose levels. Data from this portion of the trial identified the doses that are being further studied in Part 2, described below.

Part 2 is known as the “dose expansion” portion, and it is evaluating the safety and preliminary efficacy of Emi-Le in a larger number of patients with triple-negative breast cancer.

Now enrolling Part 2: This is the dose expansion portion of a Phase 1 trial evaluating the safety and efficacy of Emi-Le in patients with recurrent advanced or metastatic triple-negative breast cancer who have received 1-4 prior therapies, including at least one prior ADC.

Key requirements for patient eligibility include

  • Recurrent advanced or metastatic triple-negative breast cancer.
  • At least 18 years old.
  • Have received one, but not more than four prior therapies for advanced or metastatic tumor (and at least one of the prior therapies must have been an ADC).
  • Have had a tumor biopsy in the past 12 months, or are willing to have one done before starting treatment.

Additional eligibility criteria include factors such as prior treatments, overall health status, laboratory test results, and other protocol-defined requirements. Only a trial doctor can determine if a patient is eligible to take part in a clinical trial; however, this information may be useful to start a conversation with your doctor. If eligible, additional information about the trial and your responsibilities will be provided by your doctor.

Mersana Therapeutics is the sponsor of this clinical trial.

For more information about the trial, a list of hospitals or institutions participating in this clinical trial and/or information about your eligibility, please visit clinicaltrials.gov, discuss the trial with your doctor and/or click here to send an email to Emi-Le@mersana.com.